Refine Search

Search Results -

Term	Documents
(2 SAME 1).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	5
(L1 SAME L2).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	5

US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search:

L4			Refine Search
	Recall Text	Clear	Interrupt

Search History

DATE: Monday, August 09, 2004 Printable Copy Create Case

Set Name side by side	Query	<u>Hit</u> <u>Count</u>	Set Name result set
DB=P	PGPB, USPT, USOC, EPAB, JPAB, DWPI, TDBD; PLUR=YES; OP=ADJ		
<u>L4</u>	11 same 12	5	<u>L4</u>
<u>L3</u>	11 and 12	86	<u>L3</u>
<u>L2</u>	cardiomyopathy	5681	<u>L2</u>
<u>L1</u>	glp 1 or GLP 1 or glucagon-1 like peptide-1 or GLP-1 or glp-1 or glucagon like peptide 1	1486	<u>L1</u>

END OF SEARCH HISTORY

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: SSSPTAU188MXM

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

```
Welcome to STN International
NEWS
                 Web Page URLs for STN Seminar Schedule - N. America
NEWS
                 "Ask CAS" for self-help around the clock
                 EXTEND option available in structure searching
NEWS
        May 12
NEWS
        May 12
                Polymer links for the POLYLINK command completed in REGISTRY
NEWS
        May 27
                 New UPM (Update Code Maximum) field for more efficient patent
                 SDIs in CAplus
NEWS
                 CAplus super roles and document types searchable in REGISTRY
        May 27
NEWS
         Jun 28
                 Additional enzyme-catalyzed reactions added to CASREACT
NEWS
        Jun 28
                 ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG,
                 and WATER from CSA now available on STN(R)
NEWS
        Jul 12
                 BEILSTEIN enhanced with new display and select options,
                 resulting in a closer connection to BABS
        Jul 30
                 BEILSTEIN on STN workshop to be held August 24 in conjunction
NEWS 10
                 with the 228th ACS National Meeting
                 IFIPAT/IFIUDB/IFICDB reloaded with new search and display
NEWS 11 AUG 02
                 fields
NEWS 12
        AUG 02
                 CAplus and CA patent records enhanced with European and Japan
                 Patent Office Classifications
        AUG 02
                 STN User Update to be held August 22 in conjunction with the
NEWS 13
                 228th ACS National Meeting
        AUG 02
                 The Analysis Edition of STN Express with Discover!
NEWS 14
                 (Version 7.01 for Windows) now available
NEWS 15 AUG 04
                 Pricing for the Save Answers for SciFinder Wizard within
                 STN Express with Discover! will change September 1, 2004
NEWS EXPRESS
             JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT
              MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
              AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004
              STN Operating Hours Plus Help Desk Availability
NEWS HOURS
NEWS INTER
              General Internet Information
NEWS LOGIN
              Welcome Banner and News Items
NEWS PHONE
              Direct Dial and Telecommunication Network Access to STN
              CAS World Wide Web Site (general information)
NEWS WWW
```

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 13:30:05 ON 09 AUG 2004

SINCE FILE TOTAL ENTRY SESSION 0.21 0.21

FULL ESTIMATED COST

FILE 'CA' ENTERED AT 13:30:21 ON 09 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 13:30:21 ON 09 AUG 2004 COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'MEDLINE' ENTERED AT 13:30:21 ON 09 AUG 2004

=> s glp-1 or GLP-1 or glucacon like-peptide 1 or GLP 1 or glp 1 or glucagon like peptide 1 $\,$

L1 5995 GLP-1 OR GLP-1 OR GLUCACON LIKE-PEPTIDE 1 OR GLP 1 OR GLUCAGON LIKE PEPTIDE 1

=> s cardiomyopathy

L2 62391 CARDIOMYOPATHY

=> s 11 and 12

L3 6 L1 AND L2

=> d 1-6 ab,bib

L3 ANSWER 1 OF 6 CA COPYRIGHT 2004 ACS on STN

AB The invention provides methods for treatment and/or prevention of diabetes and diabetes-related diseases. More specifically, the methods and uses of the invention pertains to administration of an exendin-4 compound in combination with administration of a thiazolidinedione insulin sensitizer.

AN 141:47336 CA

TI Combination treatment for diabetes and related diseases using exendins and thiazolidinediones

IN Knudsen, Lotte Bjerre

PA Novo Nordisk A/S, Den.

SO PCT Int. Appl., 31 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

FAN.CNT 1																		
	PATENT NO.				KIND		DATE		APPLICATION NO.						DATE			
ΡI	WO	VO 2004050115			A2 20040617			WO 2003-DK824						20031201				
		W:	ΑE,	AG,	AL,	AM,	ΑT,	ΑU,	ΑZ,	BA,	BB,	BG,	BR,	BW,	BY,	ΒZ,	CA,	CH,
			CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FΙ,	GB,	GD,
			GE,	GH,	GM,	HR,	HU,	ID,	ΙL,	IN,	IS,	JP,	KE,	KG,	ΚP,	KR,	ΚZ,	LC,
			LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	ΜZ,	NI,	NO,
			NZ,	OM,	PG,	PH,	ΡL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SY,	ТJ,
			TM,	TN,	TR,	TT,	TZ,	UA,	UG,	UΖ,	VC,	VN,	YU,	ZA,	ZM,	ZW,	AM,	ΑZ,
			BY,	KG,	KΖ,	MD												
		RW:	BW,	GH,	GM,	KE,	LS,	MW,	ΜZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	ΑT,	BE,
			BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FI,	FR,	GB,	GR,	HU,	ΙE,	IT,	LU,
			MC,	NL,	PT,	RO,	SE,	SI,	SK,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GA,	GN,
			GQ,	GW,	ML,	MR,	NE,	SN,	TD,	TG								
PRAI	AI DK 2002-1864		Α		2002	1203												
	US 2002-431999P			P		2002	1209											

L3 ANSWER 2 OF 6 CA COPYRIGHT 2004 ACS on STN

AB Methods and uses for the treatment and prevention of cardiac and cardiovascular diseases comprising administration of a GLP
1 agonist to reduce brain natriuretic peptide (BNP) levels in plasma and/or heart tissue. The treatment can be combined with other

```
therapies such as anti-diabetic, anti-obesity, lipid modulation,
      anti-hypertensive and anti-osteoporosis therapies.
AN
      139:302514 CA
      Methods and composition for the treatment of cardiovascular diseases using
TI
      GLP-1 analogs to reduced the levels of brain natriuretic
      peptide (BNP)
      Knudsen, Liselotte Bjerre; Rolin, Bida Charlotte; Carr, Richard David;
IN
      Selmer, Johan; Larsen, Jens; Elbrond, Bodil; Nielsen, Lars Bo;
      Christoffersen, Christina
PΑ
      Novo Nordisk A/S, Den.
      PCT Int. Appl., 28 pp.
SO
      CODEN: PIXXD2
DT
      Patent
      English
LA
FAN.CNT 1
                           KIND DATE
                                                 APPLICATION NO.
      PATENT NO.
                                                                            DATE
                           ----
                                    -----
                                                  -----
                             A1 20031016 WO 2003-DK216
      WO 2003084563
ΡI
                                                                            20030402
          W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
              AE, AG, AL, AH, AT, AO, AZ, BA, BB, BG, BR, BI, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD,
               RU, TJ, TM
          RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
               GW, ML, MR, NE, SN, TD, TG
      US 2003220255
                          A1
                                  20031127
                                                  US 2003-406426
                                                                             20030403
PRAI DK 2002-499
                                     20020404
                             Α
     US 2002-375255P
                                     20020423
                             Р
                THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT 10
                ALL CITATIONS AVAILABLE IN THE RE FORMAT
L3
     ANSWER 3 OF 6 CA COPYRIGHT 2004 ACS on STN
      The invention provides a method and composition for treatment of diabetes,
AΒ
     hypertension, chronic heart failure and fluid retentive states, comprising
     administering inhibitors of neutral endopeptidase and dipeptidyl peptidase
      IV (DPP-IV) to individuals suffering from one or more of these conditions.
     Inhibition of the activity of the two enzymes will potentiate the
      insulin-releasing activity of endogenous glucagon-like
     peptide 1 (GLP-1) and other DPP-IV
      substrates, e.g. gastric inhibitory peptide (GIP). Preparation of heterocyclic
     DPP-IV inhibitors is described.
ΑN
     139:111703 CA
TI
     Method and composition using a dipeptidyl peptidase IV inhibitor-neutral
     endopeptidase inhibitor combination for treatment of diabetes,
     hypertension, chronic heart failure, and fluid retentive states
IN
     Carr, Richard David
PΑ
     Novo Nordisk A/S, Den.
SO
     PCT Int. Appl., 84 pp.
     CODEN: PIXXD2
DT
     Patent
     English
LA
FAN.CNT 1
     PATENT NO.
                           KIND
                                    DATE
                                                APPLICATION NO. DATE
                            ----
                                    -----
                                                  ______
     WO 2003057200
                            A2
                                    20030717
PΙ
                                                  WO 2003-DK17
                                                                            20030113
                                   20040624
     WO 2003057200
                            A3
          W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
              CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
              GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
              LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
```

```
PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
              UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD,
              RU, TJ, TM
          RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
              CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                                               US 2003-421465
     US 2003236272
                            A1
                                   20031225
                                                                         20030423
PRAI DK 2002-47
                            Α
                                   20020111
     US 2002-348332P
                            Ρ
                                   20020114
     WO 2003-DK17
                            A1
                                   20030113
OS
     MARPAT 139:111703
     ANSWER 4 OF 6 CA COPYRIGHT 2004 ACS on STN
L3
     Hibernating myocardium is characterized by viable myocardium with impaired
AB
     function due to localized reduced perfusion. Hibernating myocytes retain
     cellular integrity, but cannot sustain high-energy requirements of
     contraction. High plasma levels of catecholamines, such as
     norepinephrine, are believed to be predictive of mortality from
     hibernating myocardium. Likewise, high levels of catecholamines lead to
     cardiomyopathy in patients with diabetes. GLP-1
     reduces plasma norepinephrine levels, and it thus is useful in a method of
     treating hibernating myocardium or diabetic cardiomyopathy.
AN
     136:350560 CA
     Treatment of hibernating myocardium and diabetic cardiomyopathy
TI
     with a GLP-1 peptide
     Ehlers, Mario
IN
     Coolidge, Thomas R., USA
PA
SO
     PCT Int. Appl., 26 pp.
     CODEN: PIXXD2
DT
     Patent
LA
     English
FAN.CNT 1
     PATENT NO.
                         KIND
                                  DATE
                                              APPLICATION NO.
                                                                        DATE
                           ----
                                  -----
                                               -----
                          A2
PΙ
     WO 2002034285
                                  20020502
                                               WO 2001-US32559
                                                                        20011022
                                 20030515
     WO 2002034285
                           A3
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
              CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
              LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
              PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
              DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
              BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                           Α5
     AU 2002014618
                                  20020506
                                            AU 2002-14618
                                                                       20011022
     US 2002146405
                            A1
                                  20021010
                                               US 2001-982978
                                                                        20011022
                                  20030730
     EP 1330261
                           A2
                                               EP 2001-983169
                                                                        20011022
         R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
              IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
     JP 2004512311
                           T2
                                  20040422
                                               JP 2002-537336
                                                                        20011022
PRAI US 2000-241834P
                            Р
                                  20001020
     US 2000-242139P
                            Ρ
                                  20001023
                            Р
     US 2000-245234P
                                  20001103
     WO 2001-US32559
                           W
                                  20011022
L_3
     ANSWER 5 OF 6 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
     2004:62522 BIOSIS
AN
     PREV200400063083
DN
TI
     Recombinant glucagon like peptide-1
     (rGLP-1) improves survival in spontaneously hypertensive heart failure
     (SHHF) rats.
ΑU
     Nikolaidis, Lazaros A. [Reprint Author]; Hentosz, Teresa [Reprint Author];
```

- Stolarski, Carol [Reprint Author]; Elahi, Dariush; Shannon, Richard P. [Reprint Author]
- CS Allegheny General Hosp, Pittsburgh, PA, USA
- Circulation, (October 28 2003) Vol. 108, No. 17 Supplement, pp. IV-93-IV-94. print.

 Meeting Info.: American Heart Association Scientific Sessions 2003. Orlando, FL, USA. November 09-12, 2003. American Heart Association. ISSN: 0009-7322 (ISSN print).
- DT Conference; (Meeting)
 Conference; Abstract; (Meeting Abstract)
- LA English
- ED Entered STN: 28 Jan 2004 Last Updated on STN: 28 Jan 2004
- L3 ANSWER 6 OF 6 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
- AN 2004:54189 BIOSIS
- DN PREV200400051535
- TI Recombinant glucagon like peptide-1 (rGLP-1) improves clinical and functional performance in patients with advanced heart failure.
- AU Sokos, George G. [Reprint Author]; Nikolaidis, Lazaros A. [Reprint Author]; Mankad, Sunil [Reprint Author]; Germani, Judy L. [Reprint Author]; Hentosz, Teresa M. [Reprint Author]; Elahi, Dariush; Shannon, Richard P. [Reprint Author]
- CS Allegheny General Hosp, Pittsburgh, PA, USA
- SO Circulation, (October 28 2003) Vol. 108, No. 17 Supplement, pp. IV-398. print.

 Meeting Info.: American Heart Association Scientific Sessions 2003.

 Orlando, FL, USA. November 09-12, 2003. American Heart Association.

 ISSN: 0009-7322 (ISSN print).
- DT Conference; (Meeting)
 Conference; Abstract; (Meeting Abstract)
- LA English
- ED Entered STN: 21 Jan 2004 Last Updated on STN: 21 Jan 2004